Eloxx Pharmaceuticals, Inc. (ELOX) financial statements (2022 and earlier)

Company profile

Business Address 480 ARSENAL WAY
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
6/30/2017
6/30/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments42,26824,66856,27648,60624,04933811
Cash and cash equivalents42,26824,66822,49348,60624,04933811
Short-term investments  33,783    
Restricted cash and investments299564345102  
Prepaid expense500538916806267  
Other undisclosed current assets41363147488488251172
Total current assets:43,48025,89357,70950,34124,506284983
Noncurrent Assets
Operating lease, right-of-use asset1,443421924
Property, plant and equipment2161332012482785193
Deposits noncurrent assets     1051
Other noncurrent assets 30113129   
Other undisclosed noncurrent assets     5,5008,100
Total noncurrent assets:1,6595841,2383772785,5618,243
TOTAL ASSETS:45,13926,47758,94750,71824,7845,8459,226
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,5753,4056,5697,8073,423522347
Accounts payable1,3794811,8717471,53019290
Accrued liabilities4,1962,8864,6556,9381,893330256
Taxes payable 3843122   
Debt 5,2394,835  407 
Derivative instruments and hedges, liabilities     1,845 
Due to related parties3,723805403    
Other liabilities      22
Other undisclosed current liabilities657389     
Total current liabilities:9,9559,83811,8077,8073,4232,774369
Noncurrent Liabilities
Long-term debt and lease obligation12,8006,40910,927    
Long-term debt, excluding current maturities11,9966,37610,502    
Operating lease, liability80433425
Liabilities, other than long-term debt     2,2004,296
Deferred tax liabilities, net  2,2003,240
Other liabilities      100
Derivative instruments and hedges, liabilities      957
Other undisclosed noncurrent liabilities(804)(33)     
Total noncurrent liabilities:12,8006,40910,927  2,2004,296
Total liabilities:22,75516,24722,7347,8073,4234,9744,665
Stockholders' equity
Stockholders' equity attributable to parent, including:22,38410,23036,21342,91121,3618714,561
Common stock871404402360274292205
Treasury stock, value(2,190)(1,828)(1,703)(1,129)   
Additional paid in capital262,026183,250174,515129,82560,047122,402119,983
Accumulated other comprehensive income  18    
Accumulated deficit(238,323)(171,596)(137,019)(86,145)(38,960)(121,824)(115,630)
Other undisclosed stockholders' equity attributable to parent     22
Total stockholders' equity:22,38410,23036,21342,91121,3618714,561
TOTAL LIABILITIES AND EQUITY:45,13926,47758,94750,71824,7845,8459,226

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
6/30/2017
6/30/2016
Revenues
(Revenue, Net)
      75
Cost of revenue     (2,600)(7,481)
Gross profit:     (2,600)(7,406)
Operating expenses(66,018)(33,455)(50,555)(47,565)(20,390)(1,993)(3,789)
Operating loss:(66,018)(33,455)(50,555)(47,565)(20,390)(4,593)(11,195)
Nonoperating income (expense)(709)(1,122)(319)502(156)2491,994
Investment income, nonoperating     2491,994
Foreign currency transaction loss, before tax    (156)  
Other nonoperating income (expense)(709)(1,122)(319)502   
Interest and debt expense(1,259)(1,409)(1,616)(7)(824)  
Other undisclosed income from continuing operations before equity method investments, income taxes 1,4091,6167204  
Loss from continuing operations before equity method investments, income taxes:(67,986)(34,577)(50,874)(47,063)(21,166)(4,344)(9,201)
Other undisclosed income (loss) from continuing operations before income taxes1,259    (2,493)253
Loss from continuing operations before income taxes:(66,727)(34,577)(50,874)(47,063)(21,166)(6,836)(8,948)
Income tax expense (benefit)   (122) 1,040680
Net loss:(66,727)(34,577)(50,874)(47,185)(21,166)(5,796)(8,268)
Other undisclosed net loss attributable to parent    (48)  
Net loss attributable to parent:(66,727)(34,577)(50,874)(47,185)(21,214)(5,796)(8,268)
Preferred stock dividends and other adjustments     (398)(179)
Net loss available to common stockholders, diluted:(66,727)(34,577)(50,874)(47,185)(21,214)(6,194)(8,447)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
6/30/2017
6/30/2016
Net loss:(66,727)(34,577)(50,874)(47,185)(21,166)(5,796)(8,268)
Comprehensive loss:(66,727)(34,577)(50,874)(47,185)(21,166)(5,796)(8,268)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (18)18   (179)
Comprehensive loss, net of tax, attributable to parent:(66,727)(34,595)(50,856)(47,185)(21,166)(5,796)(8,447)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: